Alok Shetty

发表

Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation

P. Chaturvedi, A. Mahajan, P. Pai, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel with Mycidac-C in the second line and beyond in advanced head-and-neck cancer: A retrospective analysis from a tertiary cancer center

K. Prabhash, V. Noronha, V. Patil, 2022, Cancer Research, Statistics, and Treatment.